3 days Ago By ABMN Staff
Canaccord Genuity Group reiterated their hold rating on shares of BioMarin Pharmaceutical ( NASDAQ:BMRN – Free Report ) in a research report report published on Friday, Benzinga reports. Canaccord Genuity Group currently has a $93.00 target price on the biotechnology company’s stock.
A number of other brokerages have also recently commented on BMRN. Royal Bank of Canada reiterated a sector perform rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, September 5th.
TD Cowen decreased their price objective on BioMarin Pharmaceutical from $125.00 to $120.00 and set a buy rating for the company in a research report on Tuesday, August 6th.
Wells Fargo & Company boosted their target price on BioMarin Pharmaceutical from $110.00 to $115.00 and gave the company an overweight rating in a report on Thursday, June 27th.
Scotiabank upped their price target on BioMarin Pharmaceutical from $86.00 to $95.00 and gave the stock a sector perform rating in a research note on Thursday, September 5th.
Finally, Barclays lowered their price objective on shares of BioMarin Pharmaceutical from $111.00 to $110.00 and set an overweight rating on the stock in a research report on Tuesday, August 6th.
Eight investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $106.11.
Check Out Our Latest Stock Analysis on BioMarin Pharmaceutical BioMarin Pharmaceutical Trading Up 0.6 % BioMarin Pharmaceutical ( NASDAQ:BMRN – Get Free Report ) last posted its earnings results on Monday, August 5th. The biotechnology company reported $0.
77 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.39.
The business had revenue of $712.03 million during the quarter, compared to the consensus estimate of $660.51 million.
BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%.
As a group, equities research analysts expect that BioMarin Pharmaceutical will post 2.4 EPS for the current fiscal year. Hedge Funds Weigh In On BioMarin Pharmaceutical A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN.
Primecap Management Co. CA increased its stake in shares of BioMarin Pharmaceutical by 0.4% during the 2nd quarter.
Primecap Management Co. CA now owns 18,790,085 shares of the biotechnology company’s stock worth $1,546,988,000 after purchasing an additional 76,190 shares in the last quarter. Vanguard Group Inc.
increased its position in BioMarin Pharmaceutical by 0.4% during the first quarter. Vanguard Group Inc.
now owns 18,117,108 shares of the biotechnology company’s stock worth $1,582,348,000 after buying an additional 67,046 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of BioMarin Pharmaceutical by 79.0% in the fourth quarter.
Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company’s stock worth $1,038,907,000 after acquiring an additional 4,756,671 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 4.4% in the second quarter.
Avoro Capital Advisors LLC now owns 4,557,416 shares of the biotechnology company’s stock worth $375,212,000 after acquiring an additional 192,416 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $324,098,000. Institutional investors and hedge funds own 98.
71% of the company’s stock. About BioMarin Pharmaceutical ( Get Free Report ) BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter ..
